Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Brain Res Bull ; 174: 53-62, 2021 09.
Artigo em Inglês | MEDLINE | ID: mdl-34090933

RESUMO

Surgical intervention is necessary following nerve trauma. Tubular prostheses can guide growing axons and inserting substances within these prostheses can be positive for the regeneration, making it an alternative for the current standard tools for nerve repair. Our aim was to investigate the effects of fibrin glue BthTL when combined with a synthetic TNF mimetic-action peptide on nerve regeneration. Male Wistar rats suffered left sciatic nerve transection. For repairing, we used empty silicon tubes (n = 10), tubes filled with fibrin glue BthTL (Tube + Glue group, n = 10) or tubes filled with fibrin glue BThTL mixed with TNF mimetic peptide (Tube + Glue + Pep group, n = 10). Animals were euthanized after 45 days. We collected nerves to perform immunostaining (neurofilament, GAP43, S100-ß, NGFRp75 and Iba-1), light and transmission electron microscopy (for counting myelinated, unmyelinated and degenerated fibers; and for the evaluation of morphometric aspects of regenerated fibers) and collagen staining. All procedures were approved by local ethics committee (protocol 063/17). Tube + Glue + Pep group showed intense inflammatory infiltrate, higher Iba-1 expression, increased immunostaining for NGFRp75 receptor (which characterizes Schwann cell regenerative phenotype), higher myelin thickness and fiber diameter and more type III collagen deposition. Tube + Glue group showed intermediate results between empty tube and Tube + Glue + Pep groups for anti-NGFRp75 immunostaining, inflammation and collagen; on fiber counts, this group showed more degenerate fibers and fewer unmyelinated axons than others. Empty tube group showed superiority only in GAP43 immunostaining. A combination of BthTL glue and TNF mimetic peptide induced greater axonal regrowth and remyelination.


Assuntos
Adesivo Tecidual de Fibrina , Regeneração Nervosa/efeitos dos fármacos , Peptidomiméticos/administração & dosagem , Peptidomiméticos/farmacologia , Nervos Periféricos/efeitos dos fármacos , Fator de Necrose Tumoral alfa/administração & dosagem , Fator de Necrose Tumoral alfa/farmacologia , Animais , Axônios/efeitos dos fármacos , Colágeno/metabolismo , Imuno-Histoquímica , Masculino , Bainha de Mielina/efeitos dos fármacos , Fibras Nervosas Mielinizadas/efeitos dos fármacos , Proteínas do Tecido Nervoso/metabolismo , Peptidomiméticos/química , Ratos , Ratos Wistar , Células de Schwann/efeitos dos fármacos , Células de Schwann/ultraestrutura , Nervo Isquiático/lesões , Fator de Necrose Tumoral alfa/química
2.
PLoS One ; 16(5): e0247357, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33956804

RESUMO

BACKGROUND: Endogenous serine protease inhibitors are associated with anti-inflammatory and pro-survival signaling mediated via Low-density lipoprotein receptor-related protein 1 (LRP1) signaling. SP16 is a short polypeptide that mimics the LRP1 binding portion of alpha-1 antitrypsin. METHODS: A pilot phase I, first-in-man, randomized, double blind, placebo-controlled safety study was conducted to evaluate a subcutaneous injection at three dose levels of SP16 (0.0125, 0.05, and 0.2 mg/kg [up to 12 mg]) or matching placebo in 3:1 ratio in healthy individuals. Safety monitoring included vital signs, laboratory examinations (including hematology, coagulation, platelet function, chemistry, myocardial toxicity) and electrocardiography (to measure effect on PR, QRS, and QTc). RESULTS: Treatment with SP16 was not associated with treatment related serious adverse events. SP16 was associated with mild-moderate pain at the time of injection that was significantly higher than placebo on a 0-10 pain scale (6.0+/-1.4 [0.2 mg/kg] versus 1.5+/-2.1 [placebo], P = 0.0088). No differences in vital signs, laboratory examinations and electrocardiography were found in those treated with SP16 versus placebo. CONCLUSION: A one-time treatment with SP16 for doses up to 0.2 mg/kg or 12 mg was safe in healthy volunteers.


Assuntos
Anti-Inflamatórios/farmacologia , Voluntários Saudáveis , Peptidomiméticos/farmacologia , Adulto , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/química , Método Duplo-Cego , Feminino , Humanos , Proteína-1 Relacionada a Receptor de Lipoproteína de Baixa Densidade , Masculino , Pessoa de Meia-Idade , Peptidomiméticos/administração & dosagem , Peptidomiméticos/química , Adulto Jovem
3.
ACS Infect Dis ; 5(12): 2061-2066, 2019 12 13.
Artigo em Inglês | MEDLINE | ID: mdl-31637907

RESUMO

The emergence, prevalence, and rapid spread of New Delhi metallo-ß-lactamases (NDMs) in Gram-negative pathogens threaten our traditional regimen to treat bacterial infectious diseases. Discovery of novel NDMs inhibitors offers an alternative approach to restore the carbapenems activity. However, thus far, no clinical inhibitor of NDMs has been approved. In this study, the potential of peptides and analogues as carbapenems adjuvant in NDMs-positive pathogens was investigated. Herein, we successfully found that peptidomimetic 4 (PEP4) is a potential inhibitor of NDM enzymes. PEP4 displayed significant synergistic activity with Meropenem against NDM-expression Gram-negative bacteria in vitro. Moreover, PEP4 effectively restored Meropenem efficacy in mice infection models infected with NDM-5-positive E. coli. These data demonstrated the high potential of PEP4 as carbapenems adjuvant to address NDMs-positive Gram-negative pathogens.


Assuntos
Infecções por Bactérias Gram-Negativas/tratamento farmacológico , Meropeném/administração & dosagem , Peptidomiméticos/administração & dosagem , Inibidores de beta-Lactamases/administração & dosagem , beta-Lactamases/metabolismo , Animais , Modelos Animais de Doenças , Reposicionamento de Medicamentos , Sinergismo Farmacológico , Bactérias Gram-Negativas/efeitos dos fármacos , Bactérias Gram-Negativas/enzimologia , Bactérias Gram-Negativas/crescimento & desenvolvimento , Humanos , Meropeném/uso terapêutico , Camundongos , Estrutura Molecular , Peptidomiméticos/síntese química , Peptidomiméticos/química , Peptidomiméticos/farmacologia , Inibidores de beta-Lactamases/síntese química , Inibidores de beta-Lactamases/química , Inibidores de beta-Lactamases/farmacologia , beta-Lactamases/química
4.
Bioconjug Chem ; 30(7): 2011-2022, 2019 07 17.
Artigo em Inglês | MEDLINE | ID: mdl-31243977

RESUMO

Cell-penetrating peptides (CPPs) have emerged as powerful tools in terms of drug delivery. Those short, often cationic peptides are characterized by their usually low toxicity and their ability to transport diverse cargos inside almost any kinds of cells. Still, one major drawback is their nonselective uptake making their application in targeted cancer therapies questionable. In this work, we aimed to combine the power of a CPP (sC18) with an integrin-targeting unit (c[DKP-f3-RGD]). The latter is composed of the Arg-Gly-Asp peptide sequence cyclized via a diketopiperazine scaffold and is characterized by its high selectivity toward integrin αvß3. The two parts were linked via copper-catalyzed alkyne-azide click reaction (CuAAC), while the CPP was additionally functionalized with either a fluorescent dye or the anticancer drug daunorubicin. Both functionalities allowed a careful biological evaluation of these novel peptide-conjugates regarding their cellular uptake mechanism, as well as cytotoxicity in αvß3 integrin receptor expressing cells versus cells that do not express αvß3. Our results show that the uptake follows a "kiss-and-run"-like model, in which the conjugates first target and recognize the receptor, but translocate mainly by CPP mediation. Thereby, we observed significantly more pronounced toxic effects in αvß3 expressing U87 cells compared to HT-29 and MCF-7 cells, when the cells were exposed to the substances with only very short contact times (15 min). All in all, we present new concepts for the design of cancer selective peptide-drug conjugates.


Assuntos
Antineoplásicos/administração & dosagem , Peptídeos Penetradores de Células/química , Dicetopiperazinas/administração & dosagem , Portadores de Fármacos/química , Integrina alfaVbeta3/metabolismo , Oligopeptídeos/química , Antineoplásicos/metabolismo , Antineoplásicos/farmacologia , Linhagem Celular Tumoral , Peptídeos Penetradores de Células/metabolismo , Dicetopiperazinas/química , Dicetopiperazinas/farmacologia , Portadores de Fármacos/metabolismo , Sistemas de Liberação de Medicamentos , Humanos , Neoplasias/tratamento farmacológico , Oligopeptídeos/metabolismo , Peptidomiméticos/administração & dosagem , Peptidomiméticos/química , Peptidomiméticos/farmacologia
5.
ACS Chem Neurosci ; 10(3): 1462-1477, 2019 03 20.
Artigo em Inglês | MEDLINE | ID: mdl-30673220

RESUMO

A new generation of ligands designed to interact with the α-helix/ß-strand discordant region of the amyloid-ß peptide (Aß) and to counteract its oligomerization is presented. These ligands are designed to interact with and stabilize the Aß central helix (residues 13-26) in an α-helical conformation with increased interaction by combining properties of several first-generation ligands. The new peptide-like ligands aim at extended hydrophobic and polar contacts across the central part of the Aß, that is, "clamping" the target. Molecular dynamics (MD) simulations of the stability of the Aß central helix in the presence of a set of second-generation ligands were performed and revealed further stabilization of the Aß α-helical conformation, with larger number of polar and nonpolar contacts between ligand and Aß, compared to first-generation ligands. The synthesis of selected novel Aß-targeting ligands was performed in solution via an active ester coupling approach or on solid-phase using an Fmoc chemistry protocol. This included incorporation of aliphatic hydrocarbon moieties, a branched triamino acid with an aliphatic hydrocarbon tail, and an amino acid with a 4'- N, N-dimethylamino-1,8-naphthalimido group in the side chain. The ability of the ligands to reduce Aß1-42 neurotoxicity was evaluated by gamma oscillation experiments in hippocampal slice preparations. The "clamping" second-generation ligands were found to be effective antineurotoxicity agents and strongly prevented the degradation of gamma oscillations by physiological concentration of monomeric Aß1-42 at a stoichiometric ratio.


Assuntos
Peptídeos beta-Amiloides/toxicidade , Sistemas de Liberação de Medicamentos/métodos , Simulação de Dinâmica Molecular , Fragmentos de Peptídeos/administração & dosagem , Peptidomiméticos/administração & dosagem , Peptídeos beta-Amiloides/antagonistas & inibidores , Peptídeos beta-Amiloides/metabolismo , Animais , Linhagem Celular Tumoral , Feminino , Hipocampo/efeitos dos fármacos , Hipocampo/metabolismo , Humanos , Ligantes , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Técnicas de Cultura de Órgãos , Fragmentos de Peptídeos/antagonistas & inibidores , Fragmentos de Peptídeos/metabolismo , Fragmentos de Peptídeos/toxicidade , Peptidomiméticos/metabolismo
6.
Mol Pharm ; 15(11): 4872-4883, 2018 11 05.
Artigo em Inglês | MEDLINE | ID: mdl-30335399

RESUMO

Two potent SP1-7 peptidomimetics have been successfully radiolabeled via [11C]CO2-fixation with excellent yields, purity, and molar activity. l-[11C]SP1-7-peptidomimetic exhibited promising ex vivo biodistribution profile. Metabolite analysis showed that l-[11C]SP1-7-peptidomimetic is stable in brain and spinal cord, whereas rapid metabolic degradation occurs in rat plasma. Metabolic stability can be significantly improved by substituting l-Phe for d-Phe, preserving 70% more of intact tracer and resulting in better brain and spinal cord tracer retention. Positron emission tomography (PET) scanning confirmed moderate brain (1.5 SUV; peak at 3 min) and spinal cord (1.0 SUV; peak at 10 min) uptake for l- and d-[11C]SP1-7-peptidomimetic. A slight decrease in SUV value was observed after pretreatment with natural peptide SP1-7 in spinal cord for l-[11C]SP1-7-peptidomimetic. On the contrary, blocking using cold analogues of l- and d-[11C]tracers did not reduce the tracers' brain and spinal cord exposure. In summary, PET scanning of l- and d-[11C]SP1-7-peptidomimetics confirms rapid blood-brain barrier and blood-spinal-cord barrier penetration. Therefore, further validation of these two tracers targeting SP1-7 is needed in order to define a new PET imaging target and select its most appropriate radiopharmaceutical.


Assuntos
Imagem Molecular/métodos , Peptidomiméticos/farmacocinética , Tomografia por Emissão de Pósitrons/métodos , Compostos Radiofarmacêuticos/farmacocinética , Substância P/metabolismo , Animais , Barreira Hematoencefálica/diagnóstico por imagem , Barreira Hematoencefálica/metabolismo , Radioisótopos de Carbono/química , Avaliação Pré-Clínica de Medicamentos , Injeções Intravenosas , Masculino , Modelos Animais , Peptidomiméticos/administração & dosagem , Peptidomiméticos/química , Permeabilidade , Compostos Radiofarmacêuticos/administração & dosagem , Compostos Radiofarmacêuticos/química , Ratos , Ratos Wistar , Medula Espinal/diagnóstico por imagem , Medula Espinal/metabolismo , Distribuição Tecidual
7.
Br J Pharmacol ; 175(11): 2013-2027, 2018 06.
Artigo em Inglês | MEDLINE | ID: mdl-29352503

RESUMO

BACKGROUND AND PURPOSE: Agonists at µ-opioid receptors (µ-receptors) are used for pain management but produce adverse effects including tolerance, dependence and euphoria. The co-administration of a µ-receptor agonist with a δ-opioid receptor (δ-receptor) antagonist has been shown to produce antinociception with reduced development of some side effects. We characterized the effects of three µ-receptor agonist/δ-receptor antagonist peptidomimetics in vivo after acute and repeated administration to determine if this profile provides a viable alternative to traditional opioid analgesics. EXPERIMENTAL APPROACH: Three µ-receptor agonist / δ-receptor antagonist peptidomimetics, AAH8, AMB46 and AMB47, and morphine were evaluated for the development of tolerance and dependence after 5 days of twice daily treatment with escalating doses of drug (10-50 mg·kg-1 ). Antinociceptive effects were measured in the warm water tail withdrawal assay before and after repeated drug treatment. Physical dependence was evaluated by naltrexone-precipitated withdrawal jumping. The rewarding effects of AAH8 were evaluated using a conditioned place preference (CPP) assay with twice daily conditioning sessions performed for 5 days. KEY RESULTS: Morphine, AAH8, AMB47 and AMB46 all demonstrated acute antinociceptive effects, but repeated administration only produced tolerance in animals treated with morphine and AMB46. Injection of naltrexone precipitated fewer jumps in mice treated repeatedly with AAH8 as compared with morphine, AMB47 or AMB46. Conditioning with morphine, but not AAH8, produced significant CPP. CONCLUSIONS AND IMPLICATIONS: AAH8 may be a better alternative than traditional opioid analgesics, producing antinociception with less development of tolerance and dependence and may be less rewarding than morphine.


Assuntos
Analgésicos Opioides/administração & dosagem , Analgésicos Opioides/farmacologia , Peptidomiméticos/administração & dosagem , Peptidomiméticos/farmacologia , Receptores Opioides delta/antagonistas & inibidores , Receptores Opioides mu/agonistas , Analgésicos Opioides/química , Animais , Células CHO , Linhagem Celular Tumoral , Cricetulus , Feminino , Humanos , Ligantes , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Conformação Molecular , Peptidomiméticos/química , Ratos
8.
FASEB J ; 32(1): 369-376, 2018 01.
Artigo em Inglês | MEDLINE | ID: mdl-28904017

RESUMO

We recently reported the aptitude of a membrane-active lipopeptide (C10OOc12O) to sensitize gram-negative bacilli (GNB) to host antibacterial proteins. Here we explored the potential of harnessing such capacity in the presence of antibiotics. For this purpose, we compared Escherichia coli sensitization to antibiotics in broth and plasma; assessed inner and outer membrane damages using scanning electron microscopy, dyes, and mutant strains; and assessed the ability to affect disease course using the mouse peritonitis-sepsis model for mono- and combination therapies. We found that by altering permeability of both outer and inner membranes, subinhibitory concentrations of C10OOc12O can transiently sensitize GNB to diverse cytoplasm-targeting antibiotics in simple media. Sensitization was maintained in plasma, where C10OOc12O instigated greater bactericidal activities, including in the presence of a bacteriostatic antibiotic (erythromycin). Single-dose administrations of rifampin and C10OOc12O to E. coli-infected mice resulted in 55% vs. 0, and 36% viability, respectively, for combined and individual treatments. Combining C10OOc12O and erythromycin has similarly improved mice protection from developing fatal sepsis. Consequently, the data confirmed that C10OOc12O renders GNB sensitive to both endogenous and exogenous antibacterials, and suggested that the tripartite concomitant presence increases therapeutic efficacy synergistically. This approach might expand the available treatment options to comprise antimicrobials with low permeability and/or efflux issues.-Jammal, J., Zaknoon, F., Mor, A. Eliciting improved antibacterial efficacy of host proteins in the presence of antibiotics.


Assuntos
Antibacterianos/administração & dosagem , Peptídeos Catiônicos Antimicrobianos/administração & dosagem , Peptídeos Catiônicos Antimicrobianos/metabolismo , Infecções por Escherichia coli/tratamento farmacológico , Infecções por Escherichia coli/metabolismo , Animais , Membrana Celular/efeitos dos fármacos , Membrana Celular/ultraestrutura , Farmacorresistência Bacteriana , Sinergismo Farmacológico , Eritromicina/administração & dosagem , Escherichia coli/efeitos dos fármacos , Escherichia coli/ultraestrutura , Infecções por Escherichia coli/microbiologia , Lipopeptídeos/administração & dosagem , Lipopeptídeos/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos ICR , Peptidomiméticos/administração & dosagem , Peptidomiméticos/metabolismo , Peritonite/tratamento farmacológico , Peritonite/metabolismo , Peritonite/microbiologia , Rifampina/administração & dosagem , Sepse/tratamento farmacológico , Sepse/metabolismo , Sepse/microbiologia
9.
Pharmacogenomics J ; 18(3): 436-443, 2018 05 22.
Artigo em Inglês | MEDLINE | ID: mdl-29205207

RESUMO

Translation of drug candidates into clinical settings requires demonstration of preclinical efficacy and formal toxicology analysis for filling an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA). Here, we investigate the membrane-associated glucose response protein 78 (GRP78) as a therapeutic target in leukemia and lymphoma. We evaluated the efficacy of the GRP78-targeted proapoptotic drug bone metastasis targeting peptidomimetic 78 (BMTP-78), a member of the D(KLAKLAK)2-containing class of agents. BMTP-78 was validated in cells from patients with acute myeloid leukemia and in a panel of human leukemia and lymphoma cell lines, where it induced dose-dependent cytotoxicity in all samples tested. Based on the in vitro efficacy of BMTP-78, we performed formal good laboratory practice toxicology studies in both rodents (mice and rats) and nonhuman primates (cynomolgus and rhesus monkeys). These analyses represent required steps towards an IND application of BMTP-78 for theranostic first-in-human clinical trials.


Assuntos
Avaliação Pré-Clínica de Medicamentos , Proteínas de Choque Térmico/genética , Leucemia/tratamento farmacológico , Linfoma/tratamento farmacológico , Peptidomiméticos/administração & dosagem , Animais , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Chaperona BiP do Retículo Endoplasmático , Proteínas de Choque Térmico/antagonistas & inibidores , Humanos , Leucemia/patologia , Linfoma/patologia , Macaca fascicularis , Macaca mulatta , Camundongos , Terapia de Alvo Molecular , Peptidomiméticos/efeitos adversos , Primatas , Ratos , Estados Unidos , United States Food and Drug Administration
10.
Cancer Lett ; 416: 94-108, 2018 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-29247826

RESUMO

Coumarins are natural compounds with antioxidant, anti-inflammatory and anti-cancer potential known to modulate inflammatory pathways. Here, non-toxic biscoumarin OT52 strongly inhibited proliferation of non-small cell lung cancer cells with KRAS mutations, inhibited stem-like characteristics by reducing aldehyde dehydrogenase expression and abrogated spheroid formation capacity. This cytostatic effect was characterized by cell cycle arrest and onset of senescence concomitant with endoplasmic reticulum and Golgi stress, leading to metabolic alterations. Mechanistically, this cellular response was associated with the novel capacity of biscoumarin OT52 to inhibit STAT3 transactivation and expression of its target genes linked to proliferation. These results were validated by computational docking of OT52 to the STAT3 DNA-binding domain. Combination treatments of OT52 with subtoxic concentrations of Bcl-xL and Mcl-1-targeting BH3 protein inhibitors triggered synergistic immunogenic cell death validated in colony formation assays as well as in vivo by zebrafish xenografts.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Estresse do Retículo Endoplasmático/efeitos dos fármacos , Neoplasias Pulmonares/tratamento farmacológico , Fator de Transcrição STAT3/antagonistas & inibidores , Ensaios Antitumorais Modelo de Xenoenxerto , 4-Hidroxicumarinas/administração & dosagem , 4-Hidroxicumarinas/química , Células A549 , Animais , Morte Celular/efeitos dos fármacos , Linhagem Celular , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Citostáticos/administração & dosagem , Citostáticos/química , Sinergismo Farmacológico , Complexo de Golgi/metabolismo , Humanos , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patologia , Estrutura Molecular , Fragmentos de Peptídeos/química , Peptidomiméticos/administração & dosagem , Peptidomiméticos/química , Proteínas Proto-Oncogênicas/química , Fator de Transcrição STAT3/metabolismo , Peixe-Zebra
11.
Drug Dev Res ; 78(6): 292-299, 2017 09.
Artigo em Inglês | MEDLINE | ID: mdl-28786125

RESUMO

Preclinical Research Mimetics of Glucagon-like peptide 1 (GLP-1) represent a useful alternative or complementary treatment choice to insulin in the treatment of diabetes mellitus. The lack of hypoglycemia as a side effect when GLP-1 receptor agonists are used along with the tendency of these therapeutic agents to prevent or even reduce weight gain makes them valuable targets in therapy development. However, native GLP-1 and many of its early analogues have very short half-lives, requiring repeated treatment to maintain therapeutic levels. As all current treatments are injected subcutaneously, a large focus has been made on trying to extend the half-lives of GLP-1 analogues while retaining bioactivity. Most success in this regard has been achieved with the use of peptide-protein fusions, which are not as well suited for oral administration. However, recent work focused on the development of non-fusion peptides with increased half-lives that may be more appropriate for oral administration. This minireview discusses the structural characteristics of past and present analogues as well as the recent work conducted toward developing novel GLP-1 receptor agonists. Drug Dev Res 78 : 292-299, 2017. © 2017 Wiley Periodicals, Inc.


Assuntos
Diabetes Mellitus/tratamento farmacológico , Peptídeo 1 Semelhante ao Glucagon/análogos & derivados , Hipoglicemiantes/administração & dosagem , Peptidomiméticos/administração & dosagem , Administração Oral , Animais , Ensaios Clínicos como Assunto , Diabetes Mellitus/metabolismo , Receptor do Peptídeo Semelhante ao Glucagon 1/agonistas , Meia-Vida , Humanos , Hipoglicemiantes/química , Hipoglicemiantes/farmacologia , Peptidomiméticos/química , Peptidomiméticos/farmacologia , Relação Estrutura-Atividade
12.
Recent Pat Anticancer Drug Discov ; 12(2): 148-168, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28164756

RESUMO

BACKGROUND: Integrins are heterodimeric cell surface receptors that mediate cell-cell and cell-extracellular matrix adhesion. These molecules play a role in processes such as cell growth and proliferation, differentiation, migration, cell trafficking, besides contributing to angiogenesis and tumor development. Given their biological role, integrins have been proposed as amenable targets in medicinal chemistry. In particular, αvß3, αvß5, αvß6 and α5ß1, integrins involved in tumor angiogenesis and metastasis, have been the subject of studies aimed at the discovery of novel cancer therapeutics. A large number of peptides and peptidomimetics based on the RGD (Arg-Gly-Asp) recognition sequence were developed in the past two decades as integrin ligands. Though such ligands have not been satisfactory as anti-angiogenic agents, their use as tools to achieve selective tumor targeting of anticancer drugs has been explored. OBJECTIVE: In this review, we summarize recent literature and patent applications in which integrin peptidic and peptidomimetic ligands were conjugated to chemotherapeutic agents both with stable or cleavable bonds to achieve tumor targeted drug delivery. METHODS: Relevant recent patents and literature in this field have been considered spanning the search from 2000 to 2016. Literature and patents were examined according to the different classes of cytotoxic drug targeted to integrins. CONCLUSION: In spite of the promising features of the conjugates, none of them has entered clinical trials. New efforts are focused on innovative approaches in the field such as the synthesis of new integrin ligands able to target a single integrin type or the employment of nanoparticles based drug delivery systems.


Assuntos
Antineoplásicos/administração & dosagem , Integrinas/metabolismo , Neoplasias/tratamento farmacológico , Inibidores da Angiogênese/administração & dosagem , Inibidores da Angiogênese/química , Inibidores da Angiogênese/farmacologia , Animais , Antineoplásicos/química , Antineoplásicos/farmacologia , Sistemas de Liberação de Medicamentos , Humanos , Nanopartículas , Neovascularização Patológica/tratamento farmacológico , Neovascularização Patológica/patologia , Patentes como Assunto , Peptídeos/administração & dosagem , Peptídeos/química , Peptidomiméticos/administração & dosagem , Peptidomiméticos/química
13.
J Pept Sci ; 22(11-12): 682-688, 2016 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-27766741

RESUMO

Vibrio cholerae serogroup O1 is the main causative agent of cholera diseases defined by life threatening rice watery diarrhea. Cholera routine vaccination has failed in controlling epidemics in developing countries because of their hard and expensive production. In this study, our aim was to investigate phage displayed mimotopes that could mimic V. cholerae lipopolysaccharide (LPS). Although LPS of Vibrio, as an endotoxin, can stimulate the immune system, thereby making it a suitable candidate for cholera vaccine, its toxicity remains as a main problem. Phage particles displaying 12 amino acid peptides were selected from phage library mimicking the antigenic epitopes of LPS from vibrio. The screening was carried out using single-domain antibody fragment VHH against LPS as target through three rounds of selection. Three clones with highest affinity to VHH were selected. To find out a new and efficient vaccine against cholera, these three phage particles containing high-affinity peptides were administered to mice to investigate the active and passive immunity. Out of 20 particles, three showed the highest affinity toward VHH. ELISA was carried out with immunized mice sera using LPS and three selected phages particles individually. ETEC, Shigella sonnei, and clinical isolates were used as bacterial targets. These three selected phages (individually or in combination) could stimulate mice immune system producing active and passive immunity. The mice immunized with phage particles could protect about 14 LD50 of V. cholerae. In conclusion, these peptides are mimicking LPS and can potentially act as vaccine candidates against V. cholerae. Copyright © 2016 European Peptide Society and John Wiley & Sons, Ltd.


Assuntos
Anticorpos Monoclonais/biossíntese , Vacinas contra Cólera/administração & dosagem , Cólera/prevenção & controle , Lipopolissacarídeos/imunologia , Peptidomiméticos/administração & dosagem , Anticorpos de Domínio Único/biossíntese , Imunidade Adaptativa/efeitos dos fármacos , Animais , Anticorpos Monoclonais/imunologia , Afinidade de Anticorpos , Cólera/imunologia , Cólera/microbiologia , Vacinas contra Cólera/biossíntese , Vacinas contra Cólera/imunologia , Epitopos/química , Epitopos/imunologia , Feminino , Imunização , Lipopolissacarídeos/química , Camundongos , Biblioteca de Peptídeos , Peptidomiméticos/síntese química , Peptidomiméticos/imunologia , Anticorpos de Domínio Único/imunologia , Resultado do Tratamento , Vibrio cholerae O1/química , Vibrio cholerae O1/efeitos dos fármacos , Vibrio cholerae O1/imunologia , Vibrio cholerae O1/patogenicidade , Vírion/química , Vírion/imunologia
14.
PLoS One ; 11(8): e0162016, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27579674

RESUMO

Phage display was used to identify peptide mimics of an immunologically protective nematode glycan (CarLA) by screening a constrained C7C peptide library for ligands that bound to an anti-CarLA mAb (PAB1). Characterisation of these peptide mimotopes revealed functional similarities with an epitope that is defined by PAB1. Mimotope vaccinations of mice with three selected individual phage clones facilitated the induction of antibody responses that recognised the purified, native CarLA molecule which was obtained from Trichostrongylus colubriformis. Furthermore, these mimotopes are specifically recognised by antibodies in the saliva of animals that were immune to natural polygeneric nematode challenge. This shows that antibodies to the PAB1 epitope form part of the mucosal polyclonal anti-CarLA antibody response of nematode immune host animals. This demonstrates that the selected peptide mimotopes are of biological relevance. These peptides are the first to mimic the PAB1 epitope of CarLA, a defined larval glycan epitope which is conserved between many nematode species.


Assuntos
Epitopos/isolamento & purificação , Peptidomiméticos/isolamento & purificação , Polissacarídeos/imunologia , Trichostrongylus/imunologia , Animais , Anticorpos Anti-Helmínticos/metabolismo , Antígenos de Helmintos/imunologia , Epitopos/administração & dosagem , Epitopos/imunologia , Fezes/parasitologia , Larva/imunologia , Camundongos , Biblioteca de Peptídeos , Peptidomiméticos/administração & dosagem , Peptidomiméticos/imunologia , Vacinas Protozoárias/administração & dosagem , Vacinas Protozoárias/imunologia , Vacinas Protozoárias/isolamento & purificação , Ovinos/parasitologia , Trichostrongylus/fisiologia
15.
Circulation ; 134(7): 534-46, 2016 Aug 16.
Artigo em Inglês | MEDLINE | ID: mdl-27486162

RESUMO

BACKGROUND: L-type calcium channels (LTCCs) play important roles in regulating cardiomyocyte physiology, which is governed by appropriate LTCC trafficking to and density at the cell surface. Factors influencing the expression, half-life, subcellular trafficking, and gating of LTCCs are therefore critically involved in conditions of cardiac physiology and disease. METHODS: Yeast 2-hybrid screenings, biochemical and molecular evaluations, protein interaction assays, fluorescence microscopy, structural molecular modeling, and functional studies were used to investigate the molecular mechanisms through which the LTCC Cavß2 chaperone regulates channel density at the plasma membrane. RESULTS: On the basis of our previous results, we found a direct linear correlation between the total amount of the LTCC pore-forming Cavα1.2 and the Akt-dependent phosphorylation status of Cavß2 both in a mouse model of diabetic cardiac disease and in 6 diabetic and 7 nondiabetic cardiomyopathy patients with aortic stenosis undergoing aortic valve replacement. Mechanistically, we demonstrate that a conformational change in Cavß2 triggered by Akt phosphorylation increases LTCC density at the cardiac plasma membrane, and thus the inward calcium current, through a complex pathway involving reduction of Cavα1.2 retrograde trafficking and protein degradation through the prevention of dynamin-mediated LTCC endocytosis; promotion of Cavα1.2 anterograde trafficking by blocking Kir/Gem-dependent sequestration of Cavß2, thus facilitating the chaperoning of Cavα1.2; and promotion of Cavα1.2 transcription by the prevention of Kir/Gem-mediated shuttling of Cavß2 to the nucleus, where it limits the transcription of Cavα1.2 through recruitment of the heterochromatin protein 1γ epigenetic repressor to the Cacna1c promoter. On the basis of this mechanism, we developed a novel mimetic peptide that, through targeting of Cavß2, corrects LTCC life-cycle alterations, facilitating the proper function of cardiac cells. Delivery of mimetic peptide into a mouse model of diabetic cardiac disease associated with LTCC abnormalities restored impaired calcium balance and recovered cardiac function. CONCLUSIONS: We have uncovered novel mechanisms modulating LTCC trafficking and life cycle and provide proof of concept for the use of Cavß2 mimetic peptide as a novel therapeutic tool for the improvement of cardiac conditions correlated with alterations in LTCC levels and function.


Assuntos
Materiais Biomiméticos/administração & dosagem , Materiais Biomiméticos/metabolismo , Canais de Cálcio Tipo L/metabolismo , Sistemas de Liberação de Medicamentos/métodos , Peptidomiméticos/administração & dosagem , Peptidomiméticos/metabolismo , Sequência de Aminoácidos , Animais , Materiais Biomiméticos/química , Canais de Cálcio Tipo L/genética , Doenças Cardiovasculares/tratamento farmacológico , Doenças Cardiovasculares/metabolismo , Células Cultivadas , Feminino , Células HEK293 , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Miócitos Cardíacos/efeitos dos fármacos , Miócitos Cardíacos/metabolismo , Peptidomiméticos/química , Estrutura Secundária de Proteína , Estrutura Terciária de Proteína , Estudos Retrospectivos
16.
ChemMedChem ; 11(18): 1974-7, 2016 09 20.
Artigo em Inglês | MEDLINE | ID: mdl-27457274

RESUMO

A novel chemical platform based on branched piperazine-2,5-dione derivatives (2,5-diketopiperazines) for creating orally available biologically active peptidomimetics has been developed. The platform includes a diketopiperazine scaffold with "built-in" functionally active peptide fragments covalently attached via linkers. The concept was applied to two hemostimulatory drugs, the dipeptide thymogen (GluTrp) and the tripeptide stemokin (IleGluTrp). Preparation of a series of respective derivatives is described. Of the five synthesized analogues, three demonstrated high hemostimulatory activity in vivo on intact mice and on ex vivo irradiated bone marrow cells. Prospects of further development of the concept are discussed.


Assuntos
Células da Medula Óssea/efeitos dos fármacos , Dicetopiperazinas/farmacologia , Peptidomiméticos/síntese química , Peptidomiméticos/farmacologia , Administração Oral , Animais , Células da Medula Óssea/citologia , Proliferação de Células/efeitos dos fármacos , Dicetopiperazinas/administração & dosagem , Dicetopiperazinas/síntese química , Dicetopiperazinas/química , Relação Dose-Resposta a Droga , Injeções Intraperitoneais , Camundongos , Estrutura Molecular , Peptidomiméticos/administração & dosagem , Peptidomiméticos/química , Relação Estrutura-Atividade
17.
Int J Cardiol ; 215: 364-71, 2016 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-27128563

RESUMO

OBJECTIVES: High-density lipoprotein (HDL) infusions induce rapid improvement of experimental atherosclerosis in rabbits but their effect on ventricular function remains unknown. We aimed to evaluate the effects of the HDL mimetic peptide CER-522 on left ventricular diastolic dysfunction (LVDD). METHODS: Rabbits were fed with a cholesterol- and vitamin D2-enriched diet until mild aortic valve stenosis and hypercholesterolemia-induced LV hypertrophy and LVDD developed. Animals then received saline or 10 or 30mg/kg CER-522 infusions 6 times over 2weeks. We performed serial echocardiograms and LV histology to evaluate the effects of CER-522 therapy on LVDD. RESULTS: LVDD was reduced by CER-522 as shown by multiple parameters including early filling mitral deceleration time, deceleration rate, Em/Am ratio, E/Em ratio, pulmonary venous velocities, and LVDD score. These findings were associated with reduced macrophages (RAM-11 positive cells) in the pericoronary area and LV, and decreased levels of apoptotic cardiomyocytes in CER-522-treated rabbits. CER-522 treatment also resulted in decreased atheromatous plaques and internal elastic lamina area in coronary arteries. CONCLUSIONS: CER-522 improves LVDD in rabbits, with reductions of LV macrophage accumulation, cardiomyocyte apoptosis, coronary atherosclerosis and remodelling.


Assuntos
Estenose da Valva Aórtica/fisiopatologia , Colesterol/administração & dosagem , Hipercolesterolemia/fisiopatologia , Hipertrofia Ventricular Esquerda/tratamento farmacológico , Peptidomiméticos/administração & dosagem , Disfunção Ventricular Esquerda/tratamento farmacológico , Animais , Estenose da Valva Aórtica/induzido quimicamente , Apoptose/efeitos dos fármacos , Células Cultivadas , Colesterol/efeitos adversos , Modelos Animais de Doenças , Humanos , Hipercolesterolemia/induzido quimicamente , Hipertrofia Ventricular Esquerda/fisiopatologia , Lipoproteínas HDL/química , Macrófagos/citologia , Macrófagos/efeitos dos fármacos , Miócitos Cardíacos/citologia , Miócitos Cardíacos/efeitos dos fármacos , Peptidomiméticos/farmacologia , Coelhos , Disfunção Ventricular Esquerda/fisiopatologia
18.
Angew Chem Int Ed Engl ; 55(2): 572-5, 2016 Jan 11.
Artigo em Inglês | MEDLINE | ID: mdl-26492861

RESUMO

Drug delivery across the blood-brain barrier (BBB) is a formidable challenge for therapies targeting the central nervous system. Although BBB shuttle peptides enhance transport into the brain non-invasively, their application is partly limited by lability to proteases. The present study proposes the use of cyclic peptides derived from venoms as an affordable way to circumvent this drawback. Apamin, a neurotoxin from bee venom, was minimized by reducing its complexity, toxicity, and immunogenicity, while preserving brain targeting, active transport, and protease resistance. Among the analogues designed, the monocyclic lactam-bridged peptidomimetic MiniAp-4 was the most permeable. This molecule is capable of translocating proteins and nanoparticles in a human-cell-based BBB model. Furthermore, MiniAp-4 can efficiently deliver a cargo across the BBB into the brain parenchyma of mice.


Assuntos
Apamina/química , Peptidomiméticos/administração & dosagem , Peçonhas/administração & dosagem , Sequência de Aminoácidos , Barreira Hematoencefálica , Humanos , Modelos Biológicos , Dados de Sequência Molecular , Peptidomiméticos/química , Peptidomiméticos/farmacocinética
19.
Sci Rep ; 5: 14626, 2015 Oct 13.
Artigo em Inglês | MEDLINE | ID: mdl-26459104

RESUMO

In a mammalian oocyte, completion of meiosis is suspended until fertilization by a sperm, and the cell cycle is arrested by a biochemical activity called cytostatic factor (CSF). Emi2 is one of the CSFs, and it maintains the protein level of maturation promoting factor (MPF) by inhibiting ubiquitin ligase anaphase promoting complex/cyclosome (APC/C). Degradation of Emi2 via ubiquitin-mediated proteolysis after fertilization requires phosphorylation by Polo-like kinase 1 (Plk1). Therefore, recognition and phosphorylation of Emi2 by Plk1 are crucial steps for cell cycle resumption, but the binding mode of Emi2 and Plk1 is poorly understood. Using biochemical assays and X-ray crystallography, we found that two phosphorylated threonines (Thr(152) and Thr(176)) in Emi2 are each responsible for the recruitment of one Plk1 molecule by binding to its C-terminal polo box domain (PBD). We also found that meiotic maturation and meiosis resumption via parthenogenetic activation were impaired when Emi2 interaction with Plk1-PBD was blocked by a peptidomimetic called 103-8. Because of the inherent promiscuity of kinase inhibitors, our results suggest that targeting PBD of Plk1 may be an effective strategy for the development of novel and specific contraceptive agents that block oocyte maturation and/or fertilization.


Assuntos
Proteínas de Ciclo Celular/química , Proteínas F-Box/química , Peptidomiméticos/química , Domínios e Motivos de Interação entre Proteínas , Proteínas Serina-Treonina Quinases/química , Proteínas Proto-Oncogênicas/química , Animais , Sítios de Ligação , Proteínas de Ciclo Celular/metabolismo , Diferenciação Celular/efeitos dos fármacos , Proteínas F-Box/metabolismo , Fertilização/efeitos dos fármacos , Meiose/efeitos dos fármacos , Mesotelina , Camundongos , Modelos Moleculares , Oócitos/citologia , Oócitos/efeitos dos fármacos , Oócitos/metabolismo , Peptidomiméticos/administração & dosagem , Peptidomiméticos/farmacologia , Fosforilação , Ligação Proteica , Conformação Proteica , Proteínas Serina-Treonina Quinases/metabolismo , Proteólise , Proteínas Proto-Oncogênicas/metabolismo , Fuso Acromático/metabolismo , Relação Estrutura-Atividade , Xenopus , Quinase 1 Polo-Like
20.
Drug Des Devel Ther ; 9: 291-304, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25609915

RESUMO

Linear peptides containing the sequence WKTSRTSHY were used as lead compounds to synthesize a novel peptidomimetic antagonist of α2ß1 integrin, with platelet aggregation-inhibiting activity, named Vipegitide. Vipegitide is a 13-amino acid, folded peptidomimetic molecule, containing two α-aminoisobutyric acid residues at positions 6 and 8 and not stable in human serum. Substitution of glycine and tryptophan residues at positions 1 and 2, respectively, with a unit of two polyethylene glycol (PEG) molecules yielded peptidomimetic Vipegitide-PEG2, stable in human serum for over 3 hours. Vipegitide and Vipegitide-PEG2 showed high potency (7×10(-10) M and 1.5×10(-10) M, respectively) and intermediate efficacy (40% and 35%, respectively) as well as selectivity toward α2 integrin in inhibition of adhesion of α1/α2 integrin overexpressing cells toward respective collagens. Interaction of both peptidomimetics with extracellular active domain of α2 integrin was confirmed in cell-free binding assay with recombinant α2 A-domain. Integrin α2ß1 receptor is found on the platelet membrane and triggers collagen-induced platelet aggregation. Vipegitide and Vipegitide-PEG2 inhibited α2ß1 integrin-mediated adhesion of human and murine platelets under the flow condition, by 50%. They efficiently blocked adenosine diphosphate- and collagen I-induced platelet aggregation in platelet rich plasma and whole human blood. Higher potency of Vipegitide than Vipegitide-PEG2 is consistent with results of computer modeling of the molecules in water. These peptidomimetic molecules were acutely tolerated in mice upon intravenous bolus injection of 50 mg/kg. These results underline the potency of Vipegitide and Vipegitide-PEG2 molecules as platelet aggregation-inhibiting drug lead compounds in antithrombotic therapy.


Assuntos
Plaquetas/efeitos dos fármacos , Integrina alfa2beta1/antagonistas & inibidores , Peptídeos/química , Peptídeos/farmacologia , Peptidomiméticos/química , Peptidomiméticos/farmacologia , Agregação Plaquetária/efeitos dos fármacos , Animais , Adesão Celular/efeitos dos fármacos , Humanos , Células K562 , Camundongos , Camundongos Endogâmicos C57BL , Peptídeos/administração & dosagem , Peptidomiméticos/administração & dosagem , Polietilenoglicóis/administração & dosagem , Polietilenoglicóis/química , Polietilenoglicóis/farmacologia , Relação Estrutura-Atividade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...